Clinical Trial Update: Pharmacogenetics of SGLT2 Inhibitors [Phase 4]

View source ↗

Summary

Phase 4 trial update on pharmacogenetics of SGLT2 inhibitors; terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Gout
• Hyperuricemia

Drugs mentioned

• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Diabetes Mellitus, Gout | Phase 4 | Status: TERMINATED | Results posted: 2022-08-01